NCT03095118View on ClinicalTrials.gov

Daratumumab in Treatment of PGNMID and C3 GN

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

October 14, 2019

Study Completion Date

May 12, 2020

Conditions
Membranoproliferative Glomerulonephritis
Interventions
DRUG

Daratumumab

Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

Fernando Fervenza

OTHER

NCT03095118 - Daratumumab in Treatment of PGNMID and C3 GN | Biotech Hunter | Biotech Hunter